$RIGL
RIGEL PHARMACEUTICALS INC Stock $rigl

$rigl Overview Financials Valuation SEC Filings Company Website

2011 Form 10-K Financial Statement

#000104746912002146 Filed on March 06, 2012

Income Statement

Concept	2011	2010 Q4	2010
Revenue	$4.800M	$0.00	$125.0M
YoY Change	-96.16%	-100.0%	15525.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$21.80M	$5.910M	$25.30M
YoY Change	-13.83%	4.05%	21.05%
% of Gross Profit
Research & Development	$69.35M	$13.76M	$64.39M
YoY Change	7.7%	-31.81%	-29.04%
% of Gross Profit
Depreciation & Amortization	$1.955M	$400.0K	$1.317M
YoY Change	48.44%	17.65%	-6.13%
% of Gross Profit
Operating Expenses	$69.35M	$19.67M	$64.39M
YoY Change	7.7%	-23.91%	-29.04%
Operating Profit	-$86.37M		$35.32M
YoY Change	-344.55%		-131.52%
Interest Expense	$25.00K	$70.00K	$91.00K
YoY Change	-72.53%	600.0%	-55.17%
% of Operating Profit			0.26%
Other Income/Expense, Net	$0.00	$2.360M	$2.400M
YoY Change	-100.0%
Pretax Income	-$85.97M	-$17.24M	$37.89M
YoY Change	-326.9%	-31.29%	-133.94%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income			0.0%
Net Earnings	-$86.00M	-$17.24M	$37.90M
YoY Change	-326.91%	-31.29%	-133.99%
Net Earnings / Revenue	-1791.67%		30.32%
Basic Earnings Per Share	-$1.36		$0.73
Diluted Earnings Per Share	-$1.36	-$330.6K	$0.72
COMMON SHARES
Basic Shares Outstanding	63.33M shares		52.06M shares
Diluted Shares Outstanding	63.33M shares		52.57M shares

Balance Sheet

Concept	2011	2010 Q4	2010
SHORT-TERM ASSETS
Cash & Short-Term Investments	$247.6M	$177.3M	$177.3M
YoY Change	39.65%	33.01%	33.01%
Cash & Equivalents	$18.60M	$8.877M	$8.900M
Short-Term Investments	$229.0M	$168.4M	$168.4M
Other Short-Term Assets	$2.600M	$2.600M	$2.600M
YoY Change	0.0%	-3.7%	-3.7%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$250.2M	$179.9M	$179.9M
YoY Change	39.08%	32.3%	32.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.900M	$4.534M	$4.500M
YoY Change	8.89%	97.13%	95.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.000M	$2.235M	$2.200M
YoY Change	-9.09%	-10.6%	-12.0%
Total Long-Term Assets	$6.900M	$6.769M	$6.800M
YoY Change	1.47%	44.02%	44.68%
TOTAL ASSETS
Total Short-Term Assets	$250.2M	$179.9M	$179.9M
Total Long-Term Assets	$6.900M	$6.769M	$6.800M
Total Assets	$257.1M	$186.7M	$186.7M
YoY Change	37.71%	32.69%	32.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.600M	$1.403M	$1.400M
YoY Change	14.29%	-56.16%	-56.25%
Accrued Expenses	$9.800M	$9.200M	$9.200M
YoY Change	6.52%	-32.35%	-32.35%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$800.0K	$800.0K
YoY Change		-27.27%	-27.27%
Total Short-Term Liabilities	$11.50M	$11.33M	$11.30M
YoY Change	1.77%	-36.37%	-36.52%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$9.400M	$137.0K	$9.200M
YoY Change	2.17%	-98.88%	-24.59%
Total Long-Term Liabilities	$9.400M	$137.0K	$9.200M
YoY Change	2.17%	-98.95%	-29.77%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.50M	$11.33M	$11.30M
Total Long-Term Liabilities	$9.400M	$137.0K	$9.200M
Total Liabilities	$21.00M	$11.46M	$20.60M
YoY Change	1.94%	-62.9%	-33.33%
SHAREHOLDERS EQUITY
Retained Earnings		-$575.4M
YoY Change
Common Stock		$741.6M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$236.1M	$166.1M	$166.1M
YoY Change
Total Liabilities & Shareholders Equity	$257.1M	$186.7M	$186.7M
YoY Change	37.71%	32.69%	32.69%

Cashflow Statement

Concept	2011	2010 Q4	2010
OPERATING ACTIVITIES
Net Income	-$86.00M	-$17.24M	$37.90M
YoY Change	-326.91%	-31.29%	-133.99%
Depreciation, Depletion And Amortization	$1.955M	$400.0K	$1.317M
YoY Change	48.44%	17.65%	-6.13%
Cash From Operating Activities	-$69.38M	$10.26M	$46.74M
YoY Change	-248.44%	-144.09%	-145.48%
INVESTING ACTIVITIES
Capital Expenditures	$2.303M	-$930.0K	$3.560M
YoY Change	-35.31%	2225.0%	2424.82%
Acquisitions
YoY Change
Other Investing Activities	-$60.55M	-$23.02M	-$49.84M
YoY Change	21.49%	-59.81%	63.3%
Cash From Investing Activities	-$62.85M	-$23.95M	-$53.40M
YoY Change	17.7%	-58.22%	74.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$142.8M		$1.964M
YoY Change	7169.81%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	142.0M	510.0K	820.0K
YoY Change	17214.63%	-12.07%	-99.2%
NET CHANGE
Cash From Operating Activities	-69.38M	10.26M	46.74M
Cash From Investing Activities	-62.85M	-23.95M	-53.40M
Cash From Financing Activities	142.0M	510.0K	820.0K
Net Change In Cash	9.750M	-13.18M	-5.840M
YoY Change	-266.95%	-83.53%	-81.33%
FREE CASH FLOW
Cash From Operating Activities	-$69.38M	$10.26M	$46.74M
Capital Expenditures	$2.303M	-$930.0K	$3.560M
Free Cash Flow	-$71.68M	$11.19M	$43.18M
YoY Change	-266.01%	-148.17%	-141.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2010	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1751000	USD
CY2010	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	820000	USD
CY2010	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-53403000	USD
CY2010	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	216249000	USD
CY2010	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	46743000	USD
CY2010	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-2361000	USD
CY2010	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2029000	USD
CY2010	us-gaap	Share Based Compensation ShareBasedCompensation	16436000	USD
CY2010	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1317000	USD
CY2010	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	37890000	USD
CY2011	us-gaap	Interest Paid InterestPaid	21000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18633000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8877000	USD
CY2011	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	9756000	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	141979000	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-62848000	USD
CY2011	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	415493000	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-69375000	USD
CY2011	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-1786000	USD
CY2011	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2460000	USD
CY2011	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	153000	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	13168000	USD
CY2011	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1955000	USD
CY2009	us-gaap	Interest Paid InterestPaid	176000	USD
CY2009Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14717000	USD
CY2008Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46005000	USD
CY2009	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-31288000	USD
CY2011	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63329000	shares
CY2011	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63329000	shares
CY2011	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.36
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-85973000	USD
CY2011	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	800000	USD
CY2010	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	1144000	USD
CY2009	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	1448000	USD
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2303000	USD
CY2010	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3560000	USD
CY2009	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	141000	USD
CY2011	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	476038000	USD
CY2010	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	266092000	USD
CY2009	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	169928000	USD
CY2011	rigl	Increase Decrease In Deferred Rent And Other Long Term Liabilities IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities	-366000	USD
CY2010	rigl	Increase Decrease In Deferred Rent And Other Long Term Liabilities IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities	3028000	USD
CY2009	rigl	Increase Decrease In Deferred Rent And Other Long Term Liabilities IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities	4442000	USD
CY2011	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-244000	USD
CY2010	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-250000	USD
CY2009	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-335000	USD
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-38000	USD
CY2010	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-19000	USD
CY2009	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-960000	USD
CY2009	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	616000	USD
CY2009	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	88000	USD
CY2011	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.36
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-85973000	USD
CY2011	us-gaap	Investment Income Interest InvestmentIncomeInterest	420000	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-86368000	USD
CY2011	us-gaap	Costs And Expenses CostsAndExpenses	91118000	USD
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21768000	USD
CY2011	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	69350000	USD
CY2011	us-gaap	Contracts Revenue ContractsRevenue	4750000	USD
CY2009	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-30664000	USD
CY2009	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	14000	USD
CY2009	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	139391000	USD
CY2009	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-102779000	USD
CY2009	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-5311000	USD
CY2009	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	5215000	USD
CY2009	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2830000	USD
CY2009	us-gaap	Share Based Compensation ShareBasedCompensation	13438000	USD
CY2009	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1403000	USD
CY2009	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-111547000	USD
CY2010	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	98000	USD
CY2010	us-gaap	Interest Paid InterestPaid	84000	USD
CY2010	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-5840000	USD
CY2009	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	102155000	USD
CY2008Q4	us-gaap	Stockholders Equity StockholdersEquity	104165000	USD
CY2009	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-111955000	USD
CY2009	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	101460000	USD
CY2009	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	616000	USD
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	109867000	USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	166131000	USD
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	117000	USD
CY2010Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52271184	shares
CY2010Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52271184	shares
CY2010Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2010Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2010Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2010Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2010Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2010Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2010Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	186695000	USD
CY2010Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-575434000	USD
CY2010Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-38000	USD
CY2010Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	741551000	USD
CY2010Q4	us-gaap	Common Stock Value CommonStockValue	52000	USD
CY2010Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	137000	USD
CY2010Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	9056000	USD
CY2010Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	45000	USD
CY2010Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11326000	USD
CY2010Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	755000	USD
CY2010Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4357000	USD
CY2010Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4811000	USD
CY2010Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1403000	USD
CY2010Q4	us-gaap	Assets Assets	186695000	USD
CY2010Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2235000	USD
CY2010Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4534000	USD
CY2010Q4	us-gaap	Assets Current AssetsCurrent	179926000	USD
CY2010Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2631000	USD
CY2010Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	168418000	USD
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	71379052	shares
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71379052	shares
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	257106000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	236149000	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-661407000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6000	USD
CY2011Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	897479000	USD
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	71000	USD
CY2011Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	9313000	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11527000	USD
CY2011Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2571000	USD
CY2011Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7271000	USD
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1556000	USD
CY2011Q4	us-gaap	Assets Assets	257106000	USD
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1991000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4882000	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	250233000	USD
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2593000	USD
CY2011Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	229007000	USD
CY2011	us-gaap	Interest Expense InterestExpense	25000	USD
CY2011	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2011Q2	dei	Entity Public Float EntityPublicFloat	649682698	USD
CY2010	us-gaap	Interest Expense InterestExpense	91000	USD
CY2009	us-gaap	Interest Expense InterestExpense	203000	USD
CY2009	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40876000	shares
CY2009	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40876000	shares
CY2009	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.73
CY2009	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.73
CY2009	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-111640000	USD
CY2009	us-gaap	Investment Income Interest InvestmentIncomeInterest	600000	USD
CY2009	us-gaap	Operating Income Loss OperatingIncomeLoss	-112037000	USD
CY2009	us-gaap	Costs And Expenses CostsAndExpenses	112787000	USD
CY2009	us-gaap	Restructuring Charges RestructuringCharges	1141000	USD
CY2009	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20903000	USD
CY2009	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	90743000	USD
CY2009	us-gaap	Contracts Revenue ContractsRevenue	750000	USD
CY2010	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52573000	shares
CY2010	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52055000	shares
CY2010	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.72
CY2010	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.73
CY2010	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	37890000	USD
CY2010	us-gaap	Investment Income Interest InvestmentIncomeInterest	303000	USD
CY2010	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2361000	USD
CY2010	us-gaap	Operating Income Loss OperatingIncomeLoss	35317000	USD
CY2010	us-gaap	Costs And Expenses CostsAndExpenses	89683000	USD
CY2010	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25291000	USD
CY2010	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	64392000	USD
CY2010	us-gaap	Contracts Revenue ContractsRevenue	125000000	USD
CY2011	dei	Entity Registrant Name EntityRegistrantName	RIGEL PHARMACEUTICALS INC
CY2011	dei	Entity Central Index Key EntityCentralIndexKey	0001034842
CY2011	dei	Document Type DocumentType	10-K
CY2011	dei	Document Period End Date DocumentPeriodEndDate	2011-12-31
CY2011	dei	Amendment Flag AmendmentFlag	false
CY2011	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2011	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2011	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2011	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	71441820	shares
CY2011	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2011
CY2011	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-85929000	USD
CY2011	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	140505000	USD
CY2010	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	37864000	USD

Files In Submission

Name	View Source	Status
0001047469-12-002146-index-headers.html	Edgar Link	pending
0001047469-12-002146-index.html	Edgar Link	pending
0001047469-12-002146.txt	Edgar Link	pending
0001047469-12-002146-xbrl.zip	Edgar Link	pending
a2207753z10-k.htm	Edgar Link	pending
a2207753zex-23_1.htm	Edgar Link	pending
a2207753zex-31_1.htm	Edgar Link	pending
a2207753zex-31_2.htm	Edgar Link	pending
a2207753zex-32_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g599256.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rigl-20111231.xml	Edgar Link	completed
rigl-20111231.xsd	Edgar Link	pending
rigl-20111231_cal.xml	Edgar Link	unprocessable
rigl-20111231_def.xml	Edgar Link	unprocessable
rigl-20111231_lab.xml	Edgar Link	unprocessable
rigl-20111231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RIGL
RIGEL PHARMACEUTICALS INC Stock $rigl

2011 Form 10-K Financial Statement

#000104746912002146 Filed on March 06, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RIGL RIGEL PHARMACEUTICALS INC Stock $rigl

2011 Form 10-K Financial Statement

#000104746912002146 Filed on March 06, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RIGL
RIGEL PHARMACEUTICALS INC Stock $rigl